Leire Arreal

Leire Arreal

Auto-generated profile, based on publicly available information

Leire Arreal

CIC bioGUNE, Bizkaia Technology Park, Derio, Spain

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 June 2017 in Nature
Verified
Journal Article
Open access
PDF file
AZAmaia Zabala-Letona
Amaia Zabala-Letona
AAAmaia Arruabarrena-Aristorena
Amaia Arruabarrena-Aristorena
NMNatalia Martín-Martín
Natalia Martín-Martín
SFSonia Fernandez-Ruiz
Sonia Fernandez-Ruiz
JSJames D. Sutherland
James D. Sutherland
ACArkaitz Carracedo
Arkaitz Carracedo
MTOR complex 1 signalling regulates polyamine metabolism and thereby promotes tumorigenesis, through regulation of the stability of a key enzyme, AMD1. The mTOR pathway regulates multiple metabolic pathways in cancers but knowledge of how oncogenic signals regulate polyamine production, which is important in spreading cancer cells, is limited. Arkaitz Carracedo and colleagues add to the existing knowledge. Using a mixture of metabolic analysis techniques, they show that mTOR signalling regulates polyamine metabolism and thereby promotes tumorigenesis through regulation of the stability of a key enzyme, AMD1. They validated this pathway in mouse and human cancer specimens and found that ADM1 is upregulated in prostate cancer specimens with activated mTORC1. This adds to the complexity of cancer cell metabolism and offers new therapeutic avenues. Activation of the PTEN–PI3K–mTORC1 pathway consolidates metabolic programs that sustain cancer cell growth and proliferation1,2. Here we show that mechanistic target of rapamycin complex 1 (mTORC1) regulates polyamine dynamics, a metabolic route that is essential for oncogenicity. By using integrative metabolomics in a mouse model3 and human biopsies4 of prostate cancer, we identify alterations in tumours affecting the production of decarboxylated S-adenosylmethionine (dcSAM) and polyamine synthesis. Mechanistically, this metabolic rewiring stems from mTORC1-dependent regulation of S-adenosylmethionine decarboxylase 1 (AMD1) stability. This novel molecular regulation is validated in mouse and human cancer specimens. AMD1 is upregulated in human prostate cancer with activated mTORC1. Conversely, samples from a clinical trial with the mTORC1 inhibitor everolimus5 exhibit a predominant decrease in AMD1 immunoreactivity that is associated with a decrease in proliferation, in line with the requirement of dcSAM production for oncogenicity. These findings provide fundamental information about the complex regulatory landscape controlled by mTORC1 to integrate and translate growth signals into an oncogenic metabolic program.

24 August 2016 in Nature Communications
Verified
Journal Article
Open access
PDF file
NMNatalia Martín-Martín
Natalia Martín-Martín
MPMarco Piva
Marco Piva
JUJelena Urosevic
Jelena Urosevic
PAPaula Aldaz
Paula Aldaz
JSJames Sutherland
James Sutherland
ACArkaitz Carracedo
Arkaitz Carracedo
Patient stratification has been instrumental for the success of targeted therapies in breast cancer. However, the molecular basis of metastatic breast cancer and its therapeutic vulnerabilities remain poorly understood. Here we show that PML is a novel target in aggressive breast cancer. The acquisition of aggressiveness and metastatic features in breast tumours is accompanied by the elevated PML expression and enhanced sensitivity to its inhibition. Interestingly, we find that STAT3 is responsible, at least in part, for the transcriptional upregulation of PML in breast cancer. Moreover, PML targeting hampers breast cancer initiation and metastatic seeding. Mechanistically, this biological activity relies on the regulation of the stem cell gene SOX9 through interaction of PML with its promoter region. Altogether, we identify a novel pathway sustaining breast cancer aggressiveness that can be therapeutically exploited in combination with PML-based stratification.

1 October 2019 in Cell Death & Differentiation
Verified
Journal Article
Open access
PDF file
LALeire Arreal
Leire Arreal
MPMarco Piva
Marco Piva
SFSonia Fernández
Sonia Fernández
ARAjinkya Revandkar
Ajinkya Revandkar
ACAriane Schaub- Clerigué
Ariane Schaub- Clerigué
ACArkaitz Carracedo
Arkaitz Carracedo
Oncogene addiction postulates that the survival and growth of certain tumor cells is dependent upon the activity of one oncogene, despite their multiple genetic and epigenetic abnormalities. This phenomenon provides a foundation for molecular targeted therapy and a rationale for oncogene-based stratification. We have previously reported that the Promyelocytic Leukemia protein (PML) is upregulated in triple negative breast cancer (TNBC) and it regulates cancer-initiating cell function, thus suggesting that this protein can be therapeutically targeted in combination with PML-based stratification. However, the effects of PML perturbation on the bulk of tumor cells remained poorly understood. Here we demonstrate that TNBC cells are addicted to the expression of this nuclear protein. PML inhibition led to a remarkable growth arrest combined with features of senescence in vitro and in vivo. Mechanistically, the growth arrest and senescence were associated to a decrease in MYC and PIM1 kinase levels, with the subsequent accumulation of CDKN1B (p27), a trigger of senescence. In line with this notion, we found that PML is associated to the promoter regions of MYC and PIM1, consistent with their direct correlation in breast cancer specimens. Altogether, our results provide a feasible explanation for the functional similarities of MYC, PIM1, and PML in TNBC and encourage further study of PML targeting strategies for the treatment of this breast cancer subtype.

15 January 2018 in Cancer Research
Verified
Journal Article
Open access
PDF file
NMNatalia Martín-Martín
Natalia Martín-Martín
AZAmaia Zabala-Letona
Amaia Zabala-Letona
SFSonia Fernández-Ruiz
Sonia Fernández-Ruiz
LALeire Arreal
Leire Arreal
LCLaura Camacho
Laura Camacho
ACArkaitz Carracedo
Arkaitz Carracedo
The nuclear receptor PPAR-β/δ (PPARD) has essential roles in fatty acid catabolism and energy homeostasis as well as cell differentiation, inflammation, and metabolism. However, its contributions to tumorigenesis are uncertain and have been disputed. Here, we provide evidence of tumor suppressive activity of PPARD in prostate cancer through a noncanonical and ligand-independent pathway. PPARD was downregulated in prostate cancer specimens. In murine prostate epithelium, PPARD gene deletion resulted in increased cellularity. Genetic modulation of PPARD in human prostate cancer cell lines validated the tumor suppressive activity of this gene in vitro and in vivo. Mechanistically, PPARD exerted its activity in a DNA binding-dependent and ligand-independent manner. We identified a novel set of genes repressed by PPARD that failed to respond to ligand-mediated activation. Among these genes, we observed robust regulation of the secretory trefoil factor family (TFF) members, including a causal and correlative association of TFF1 with prostate cancer biology in vitro and in patient specimens. Overall, our results illuminate the oncosuppressive function of PPARD and understanding of the pathogenic molecular pathways elicited by this nuclear receptor. Significance: These findings challenge the presumption that the function of the nuclear receptor PPARβ/δ in cancer is dictated by ligand-mediated activation. Cancer Res; 78(2); 399–409. ©2017 AACR.

31 October 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
ACAlfredo Caro-Maldonado
Alfredo Caro-Maldonado
LCLaura Camacho
Laura Camacho
AZAmaia Zabala-Letona
Amaia Zabala-Letona
VTVerónica Torrano
Verónica Torrano
SFSonia Fernández-Ruiz
Sonia Fernández-Ruiz
ACArkaitz Carracedo
Arkaitz Carracedo
Prostate cancer is diagnosed late in life, when co-morbidities are frequent. Among them, hypertension, hypercholesterolemia, diabetes or metabolic syndrome exhibit an elevated incidence. In turn, prostate cancer patients frequently undergo chronic pharmacological treatments that could alter disease initiation, progression and therapy response. Here we show that treatment with anti-cholesterolemic drugs, statins, at doses achieved in patients, enhance the pro-tumorigenic activity of obesogenic diets. In addition, the use of a mouse model of prostate cancer and human prostate cancer xenografts revealed that in vivo simvastatin administration alone increases prostate cancer aggressiveness. In vitro cell line systems supported the notion that this phenomenon occurs, at least in part, through the direct action on cancer cells of low doses of statins, in range of what is observed in human plasma. In sum, our results reveal a prostate cancer experimental system where statins exhibit an undesirable effect, and warrant further research to address the relevance and implications of this observation in human prostate cancer.